Search Result

Results for "

enantiomeric

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (1) Adrenergic Receptor (2) Biochemical Assay Reagents (2) Calcium Channel (2) CXCR (1) Epigenetic Reader Domain (1) Histone Acetyltransferase (1) HIV (1) Isotope-Labeled Compounds (1) Lipase (1) NOD-like Receptor (NLR) (1) VD/VDR (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (3) Endocrinology (2) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)
Oligonucleotides:	Nucleosides and their Analogs (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103237

L-Adenosine	Adenosine Deaminase	Neurological Disease
L-Adenosine is a metabolically stable enantiomeric analog and also is a potential probe. L-Adenosine has weakly inhibitory adenosine deaminase (ADA) activity with an K_i value of 385 μM. L-Adenosine can be used for the research of adenosine uptake and accumulation .

HY-101027A

GSK4028 1 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
GSK4028 is the enantiomeric negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC₅₀ of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.

HY-W250446

(R)-Methyl 3-hydroxydecanoate	Biochemical Assay Reagents	Others
(R)-Methyl 3-hydroxydecanoate is an enantiomerically pure hydroxylated fatty acid methyl ester. The hydroxyl group enables further derivatization or replacement with other reactive functional groups.

HY-Y1422I

Lipase AK	Lipase	Others
Lipase AK comes from Pseudomonas fluorescens and shows good applicability in ester synthesis of food industry, the biofuel synthesis, the synthesis of enantiomeric pure chiral drugs and so on .

HY-34849

(R)-(-)-1-(9-Anthryl)-2,2,2-trifluoroethanol	Biochemical Assay Reagents	Others
(R)-(-)-1-(9-Anthryl)-2,2,2-trifluoroethanol is utilized as a chiral shift reagent for determining enantiomeric ratios. Additionally, (R)-(-)-1-(9-Anthryl)-2,2,2-trifluoroethanol can be employed for nuclear magnetic resonance (NMR) optical purity determination .

HY-129244

Levamlodipine (gentisate) (S)-Amlodipine (gentisate); Levoamlodipine (gentisate)	Calcium Channel	Cardiovascular Disease
Levamlodipine gentisate ((S)-Amlodipine gentisate) is a pharmacologically active amino ester with calcium channel blocker activity. Levamlodipine gentisate is used as an antihypertensive and antianginal compound. The enantiomeric purity of levamlodipine gentisate can be determined by a fast capillary electrophoresis method. The highest resolution of levamlodipine gentisate reached 9.8, indicating its potential application in compound analysis .

HY-130494

(±)11(12)-EET 11,12-EET	NOD-like Receptor (NLR)	Cardiovascular Disease Inflammation/Immunology
(±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective .

HY-121814A

(R)-Acenocoumarol (R)-Acenocoumarin; (R)-Nicoumalone	VD/VDR	Cardiovascular Disease
(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting and orally active anticoagulant, like Warfarin (HY-B0687), works by inhibiting vitamin K epoxide reductase. (R)-Acenocoumarol has a greater in vivo anticoagulant potency than Warfarin. (R)-Acenocoumarol has a single chiral center that produces two different enantiomeric forms. (R)-Acenocoumarol has a longer plasma elimination half-life (6.6 h) and a slower plasma clearance rate (1.9 L/h) than the (S)-enantiomer, resulting in a stronger in vivo anticoagulant effect.

HY-N12962

11S(12R)-EET	Others	Others
11S(12R)-EET is a dominant enantiomer of epoxytrienoic acid (EET) that is metabolized at a higher rate in rat organs. It shows enantiomeric-dependent reaction selectivity in hydration, especially in the case of 11,12-EET, where water addition is non-regioselective, while in 8,9-EET, water addition occurs mainly at the C9 position. In addition, 11S(12R)-EET generates diol products with specific stereochemistry through enzymatic hydration reactions, which are affected by the selective recognition of epoxidases, reaction conversion rates, and substrate binding parameters .

HY-111224

GSK812397	HIV CXCR	Infection
GSK812397 is a CXCR4 antagonist with potential for the treatment of HIV infection. To evaluate the clinical potential of GSK812397, kilogram-scale agent candidates are needed. Here, an improved, scalable synthetic route for the CXCR4 antagonist GSK812397 is described. This new route has been scaled up in a 50-liter stationary facility to obtain 1.2 kg of agent substance in 20% overall yield and >99% chemical and enantiomeric purity in five steps. CXC chemokine receptor 4 (CXCR4) is a 7-transmembrane protein that functions in part as a host co-receptor for multiple strains of HIV-1. It is thought that targeting CXCR4 will help inhibit the replication of several late cytopathic viruses; therefore, CXCR4 antagonists are one of the most promising new classes of experimental anti-HIV agents. GSK812397 is a potent CXCR4 antagonist and is therefore a candidate for investigation for the treatment of HIV infection.

HY-132184

5,6-Epoxyeicosatrienoic acid 5,6-EET; (±)5,6-EpETrE	Adrenergic Receptor Calcium Channel	Endocrinology
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11 5,6-EET-d₁₁; (±)5,6-EpETrE-d₁₁	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12962

11S(12R)-EET	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Others
11S(12R)-EET is a dominant enantiomer of epoxytrienoic acid (EET) that is metabolized at a higher rate in rat organs. It shows enantiomeric-dependent reaction selectivity in hydration, especially in the case of 11,12-EET, where water addition is non-regioselective, while in 8,9-EET, water addition occurs mainly at the C9 position. In addition, 11S(12R)-EET generates diol products with specific stereochemistry through enzymatic hydration reactions, which are affected by the selective recognition of epoxidases, reaction conversion rates, and substrate binding parameters .

Cat. No.	Product Name	Chemical Structure

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11
5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

5,6-Epoxyeicosatrienoic acid-d11

5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

Cat. No.	Product Name		Classification

HY-103237

L-Adenosine		Nucleosides and their Analogs
L-Adenosine is a metabolically stable enantiomeric analog and also is a potential probe. L-Adenosine has weakly inhibitory adenosine deaminase (ADA) activity with an K_i value of 385 μM. L-Adenosine can be used for the research of adenosine uptake and accumulation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks